Novoheart Holdings Inc. (NVH:TSX-V) Investor Relations Material

Overview

Novoheart is a groundbreaking stem cell biotechnology company that has created miniature living human heart pumps for drug discovery. It is the only company in the world that has engineered such prototypes, which can revolutionize drug development, saving both time and money. Novoheart's bio-artificial human heart constructs are made using state-of-the-art and proprietary stem cell and bioengineering approaches, which are utilized by global pharmaceutical and biotech companies for preclinical testing. The company has offices and laboratories in the United States, Canada, and Hong Kong.

Frequently Asked Questions

What is Novoheart Holdings Inc.'s ticker?

Novoheart Holdings Inc.'s ticker is NVH

What exchange is Novoheart Holdings Inc. traded on?

The company's shares trade on the TSX-V stock exchange

Where are Novoheart Holdings Inc.'s headquarters?

They are based in Irvine, California

How many employees does Novoheart Holdings Inc. have?

There are 11-50 employees working at Novoheart Holdings Inc.

What is Novoheart Holdings Inc.'s website?

It is http://www.novoheart.com/hk/home

What type of sector is Novoheart Holdings Inc.?

Novoheart Holdings Inc. is in the Healthcare sector

What type of industry is Novoheart Holdings Inc.?

Novoheart Holdings Inc. is in the Biotechnology industry

Who are Novoheart Holdings Inc.'s peers and competitors?

The following five companies are Novoheart Holdings Inc.'s industry peers:

- Marinus Pharmaceuticals

- Eiger BioPharmaceuticals

- BioDelivery Sciences International Inc

- Pieris Pharmaceuticals

- Cynata Therapeutics Limited